ORLANDO, Fla. - s4story -- The fentanyl crisis remains one of America's most serious public-health challenges. While recent national data show meaningful improvement, the scale of the problem remains enormous. According to the CDC, 47,735 U.S. overdose deaths in 2024 involved synthetic opioids other than methadone, a category that includes fentanyl and fentanyl analogs.

Importantly, there are two very different fentanyl problems. Illicitly manufactured fentanyl is responsible for the majority of fentanyl-related harms, while pharmaceutical fentanyl remains an important medication used for severe pain. The CDC notes that pharmaceutical fentanyl can be prescribed in transdermal patches and that those patches can be diverted for misuse.

That second issue is where Nutriband Inc. (N A S D A Q: NTRB) $NTRB is attempting to make a difference.

AVERSA™: Targeting Abuse and Accidental Exposure

Nutriband's lead development program is AVERSA™ Fentanyl, an abuse-deterrent transdermal fentanyl system designed to incorporate Nutriband's proprietary AVERSA™ technology into a fentanyl patch.

The company's technology is intended to incorporate aversive agents into transdermal patches to help deter abuse, misuse, diversion and accidental exposure while maintaining access to the medication for patients who legitimately require it.

That distinction is critical.

Nutriband is not claiming to solve the illicit fentanyl crisis by itself. Instead, its potential contribution is focused on improving the safety profile of legitimate pharmaceutical transdermal medications that contain fentanyl or other drugs with abuse potential.

More on S For Story

• Gem Publishers Highlights Professional Book Publishing Services for Authors
• Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
• TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
• Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
• Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales

And that could address a meaningful, preventable portion of fentanyl-related harm.

A Look Inside America's Fentanyl Crisis

A new video examining the fentanyl crisis across the United States also features Nutriband CEO Gareth Sheridan.

The video's description explains:

"In this video I travel across the United States to investigate the fentanyl crisis that is destroying major cities across America. I speak with journalist and fentanyl researchers like Gareth Sheridan (CEO of Nutriband) to discover what is taking place in each major city from Portland, Seattle, LA and Philadelphia."

Watch the Fentanyl Crisis Investigation Featuring Gareth Sheridan

The appearance provides another opportunity for Sheridan to discuss the broader fentanyl problem and Nutriband's approach to improving the safety of prescription transdermal fentanyl.

Why This Matters for NTRB

The potential significance of AVERSA™ goes beyond simply creating another fentanyl patch.

Nutriband has designed the technology as a platform, meaning AVERSA™ could potentially be incorporated into multiple transdermal medications with abuse potential.

The company has previously reported that its AVERSA™ technology is protected by an international intellectual-property portfolio, while AVERSA™ Fentanyl remains its lead development program. Nutriband has estimated potential peak annual U.S. sales of approximately $80 million to $200 million for the product, although that is a company estimate and not a guarantee of future sales.

The development program is also moving through the regulatory pathway. Nutriband reported completing a Type C meeting with the FDA concerning Chemistry, Manufacturing and Controls plans for AVERSA™ Fentanyl, with the company working toward an IND filing supporting a Human Abuse Potential study.

More on S For Story

• Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
• Wordeee Publishes Dream & Scheme Like a Wocstar by Gayle Jennings O'Byrne
• Wordeee Publishes "Feelings Are Weird" by Natasha Moulton-Levy
• Maryland Writers Take On the Evolving World of AI and Authorship
• ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains

More recently, Nutriband announced that it received a USPTO Notice of Publication for commercial brand-name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The company said that, once allowed, it plans to submit the commercial worldwide brand name to the FDA and other international regulatory agencies.

A Different Kind of Fentanyl Opportunity

For NTRB investors, the larger story is not that Nutriband can eliminate America's fentanyl crisis. No single technology can do that.

The more specific opportunity is whether AVERSA™ can make legitimate transdermal fentanyl safer by reducing the potential for abuse, diversion and accidental exposure.

With fentanyl continuing to represent a major component of America's overdose crisis, technologies designed to reduce preventable harm remain highly relevant.

Nutriband $NTRB is attempting to bring a different tool to that fight — one focused not on illicit fentanyl itself, but on making pharmaceutical transdermal fentanyl potentially safer for patients, families and communities.

That makes the continued development of AVERSA™ Fentanyl an important story to watch as Nutriband moves toward its next regulatory and commercialization milestones.

For more information on NTRB visit: https://www.nutriband.com

Nutriband, Inc.
121 South Orange Avenue
Suite 1500
Orlando, Fl 32801
Phone: 407-377-6695
Email: info@nutriband.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website